Unknown PHASE2 INTERVENTIONAL 2-arm NCT05055414

Arformoterol/Budesonide for COVID-19 (ABC)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of UI030 in COVID-19 Patients

Sponsor: Korea United Pharm. Inc.

Conditions Coronavirus Infection

Interventions UI030

Updated 4 times since 2021 Last updated: Sep 23, 2021 Started: Nov 1, 2021 Primary completion: Oct 1, 2022 Completion: Nov 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Coronavirus Infection and is currently ongoing. Korea United Pharm. Inc. leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Oct 2021 — Oct 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korea United Pharm. Inc.

Data source: Korea United Pharm. Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.